DE-ASTRAZENECA
AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector.
Evinova will prioritise bringing to market established and scaled digital technology solutions already being used globally by AstraZeneca to optimise clinical trial design and delivery. This will reduce the time and cost of developing new medicines, bring care closer to home for patients and reduce the burden on health systems. Evinova will also pursue opportunities in digital remote patient monitoring and digital therapeutics with a pipeline of digital innovations in these areas.
Drawing on AstraZeneca’s deep experience of developing novel therapeutics and with insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions to pharma, biotech and CROs to support clinical research globally. The technologies have already been used in the successful delivery of multiple AstraZeneca-sponsored clinical trials in over 40 countries.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “The future of medicine development can be accelerated with digital solutions. We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.”
Cristina Duran, President of Evinova, said: “We are excited to bring the portfolio of globally-scaled digital solutions developed to serve AstraZeneca’s drug development pipeline to the wider life sciences community. We believe this will help propel the sector forward in digital health, as we know healthcare professionals and regulators need digital solutions that work across pharma and support patients broadly. Coming from within the sector and with proven experience, Evinova will be uniquely placed to deliver science-based, evidence-led and human experience-driven solutions with the aim of improving patient experience and outcomes.”
Globally-leading CROs Parexel and Fortrea have entered into agreements to offer Evinova digital health solutions to their wide customer base. To accelerate industry adoption and sustain and expand the global reach of its digital products, Evinova is collaborating with Accenture and Amazon Web Services.
Evinova will combine clinical and regulatory experience gained at AstraZeneca with its deep expertise in digital technology spanning strategy and development, digital product development, data science and AI, user experience design and behavioural science. In addition to digital solutions, Evinova will offer custom scientific solutions, including remote patient monitoring and novel endpoint solutions, as well as trial design and consulting services.
Notes
Evinova products and solutions
Evinova has co-created with patients the Evinova drug development suite, a suite of digital solutions that aims to bring benefits to all participants – patients, healthcare professionals and researchers. The suite includes:
Evinova unified trial solution: A global GxP-validated solution for patients, clinical trial site staff and clinical trial sponsor staff to improve delivery of clinical trials. It enables the delivery of traditional, hybrid and decentralised clinical trials while enhancing the patient experience. The unified trial solution supports direct collection of primary and secondary endpoint data including novel digitally-enabled endpoints and connected medical devices and sensors at both the trial site and patient’s home. It also supports services for virtual visits including direct-to-patient delivery of medicines, telehealth, remote patient monitoring and human biological sample tracking. Patient interaction is available through an easy-to-use, engaging patient app available in more than 40 countries and 80 languages. Site interaction is available through a single-sign-on portal.
Evinova study design and planning: Uses AI and machine learning algorithms to aide clinical development and operations teams to design the optimal study considering critical design variables. Teams can design their study, get automatic costings and assess operational feasibility based on actual data from that indication at a country and site level. They can view historic data and forecast future trends. The module also contains models to estimate the study’s carbon footprint and impact on patient experience. Teams can accelerate decision-making through collaboration and scenario comparison capabilities.
Evinova portfolio management: Supports clinical programme and trial management, reporting and governance through transparent real-time insights and predictive analytics. It provides a complete picture of the portfolio across all phases and allows for tracking of clinical programmes and trials at global, regional, country and site level. It uses predictive algorithms to provide future key milestones, enabling study leaders to understand deviations from plans and supporting appropriate intervention.
Digital health
The application of digital health technologies is seen as a solution to reduce healthcare costs, while also helping to improve patient experience and outcomes. Starting from around 6% of GDP in 2006-10, the combined public health and long-term care expenditure for OECD countries is projected to reach at least 9.5% in 2060. In BRIICS countries, spending ratios will also increase significantly, reaching around 10% of GDP by 2060 unless cost-containment policies are implemented.1 Based on 2018 healthcare spend information, McKinsey estimates that digital health interventions alone have the potential to save the US healthcare system nearly $500bn if fully adopted.2
Digital health is a large (+$900bn by 2032) and growing (13.6% CAGR 2022-2032) market. The market for R&D digital health and care delivery with remote patient monitoring, together make up approximately 60% of the total digital health market3. The remaining 40% consists of screening and diagnostics, wellness and disease prevention, supply of therapies and digital pharmacies.
Digital health technology and clinical research
A significant part of the cost and time of the drug development process is in the clinical trials, rather than designing molecules. However, they are vital to the drug development and approval process and critical in enabling access to innovative medicines. Studies estimate that it now costs up to $2bn to bring a new drug to market4 and according to one study the average length of time from the start of clinical testing to approval is 7.1 years.5 Across the industry, almost 80% of clinical trials fail to meet recruiting timelines6 and only 3-5% of eligible cancer patients join a clinical trial.7 Many groups, including marginalised racial and ethnic groups, women, and other populations are underrepresented in clinical trials.8
A recent AstraZeneca article published in Nature Medicine, lead author Cristina Duran, demonstrated that the implementation of digital health technology in clinical trials can improve the patient experience with accelerated timelines and reduced costs.9
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
Evinova
Evinova is a health-tech business, accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, from the inside. Through our application of science-based expertise, evidence-led rigour, and human experience-driven insight, our digital solutions are deliberately designed so that everyone can reach better health outcomes together. Evinova is a health-tech business within the AstraZeneca Group.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
References
- OECD. What future for health spending? Available at: https://www.oecd.org/economy/health-spending.pdf. Accessed November 2023.
- McKinsey & Company. Healthtech in the fast lane: What is fueling investor excitement? Available at: https://www.mckinsey.com/industries/life-sciences/our-insights/healthtech-in-the-fast-lane-what-is-fueling-investor-excitement. Accessed November 2023.
- Precedence Research. Digital Health Market (By Component: Software, Hardware, and Services; By Technology: Telehealthcare [Telehealth and Telecare], mHealth [Apps and Wearables], Digital Health Systems [E-prescribing Systems and Electronic Health Records], and Health Analytics) - Global Market Size, Trends Analysis, Segment Forecasts, Regional Outlook 2023 – 2032. Available at: https://www.precedenceresearch.com/digital-health-market. Accessed November 2023.
- Deloitte. Deloitte pharma study: Drop-off in returns on R&D investments. Available at: https://www2.deloitte.com/ch/en/pages/press-releases/articles/deloitte-pharma-study-drop-off-in-returns-on-r-and-d-investments-sharp-decline-in-peak-sales-per-asset.html. Accessed November 2023.
- Deloitte. Deloitte pharma study: Drop-off in returns on R&D investments. Available at: https://www2.deloitte.com/ch/en/pages/press-releases/articles/deloitte-pharma-study-drop-off-in-returns-on-r-and-d-investments-sharp-decline-in-peak-sales-per-asset.html. Accessed November 2023.
- Clinical Trials Arena. Clinical trial delays: America’s patient recruitment dilemma. Available at: https://www.clinicaltrialsarena.com/features/featureclinical-trial-patient-recruitment/. Accessed November 2023.
- Baquet, C.R., Commiskey, P., Daniel Mullins, C., Mishra, S.I., Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detect Prev. 2006;30(1):24-33. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276312/. Accessed November 2023.
- Schwartz, A.L, Aslan, M., Morris, A.M., Halpern, S.D., Why diverse clinical trial participation matters. N Engl J Med 2023; 388:1252-1254. Available at: https://www.nejm.org/doi/full/10.1056/NEJMp2215609#article_references. Accessed November 2023.
- Durán, C.O., Bonam, M., Björk, E. et al. Implementation of digital health technology in clinical trials: the 6R framework. Nat Med (2023). Available at: https://doi.org/10.1038/s41591-023-02489-z. Accessed November 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120504578/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Coca-Cola Company Names New Leader for Europe Operating Unit18.7.2025 21:00:00 CEST | Press release
The Coca-Cola Company today announced that Luisa Ortega will become president of the Europe operating unit effective Sept. 1, succeeding Nikos Koumettis, who will retire in 2026 after a 25-year career with the company. Koumettis will remain with the company through Feb. 28, 2026, as a senior advisor. He will also serve on the board of directors of Hindustan Coca-Cola Beverages Pvt. Ltd., a company-owned bottler in India. Ortega joined Coca-Cola in 2019 and currently serves as president of the Africa operating unit. In this role, she leads a complex business that operates across 54 markets. Koumettis has led the Europe operating unit since it was created in 2021. “Luisa has done an outstanding job leading our African business, where our system has continued to make major investments to serve growing markets on the continent,” said Henrique Braun, Executive Vice President and Chief Operating Officer of The Coca-Cola Company. “As head of Europe, she will bring great international experien
NFL Running Back Derrick Henry Joins Amazfit as Athlete Ambassador18.7.2025 15:00:00 CEST | Press release
Henry to utilize Amazfit products to optimize health, recovery and performance as he enters his 10th NFL season Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced Baltimore Ravens running back Derrick Henry as the newest elite athlete to join its growing roster of ambassadors. Known for his rare combination of speed and strength, Henry will utilize Amazfit wearables to power every phase of his training, recovery and sleep as he prepares for his 10th NFL season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250718322498/en/ Derrick Henry is the newest elite athlete to join Amazfit's growing roster of ambassadors. As one of the most prolific running backs of his generation, Henry has amassed an impressive array of accolades during his career, including NFL Offensive Player of the Year, two rushing titles, and five Pro Bowl selections. With Amazfit as his official smart wearable partne
Qualcomm Announces Quarterly Cash Dividend18.7.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on September 25, 2025, to stockholders of record at the close of business on September 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensin
MultiBank Group Confirms $MBG Token Listings on MEXC and Gate.io on TGE Day in Addition to MultiBank.io and Uniswap18.7.2025 14:34:00 CEST | Press release
MultiBank Group, the world’s largest & most regulated financial derivatives institution, is proud to announce that its highly anticipated $MBG Token will be listed on two new major global cryptocurrency exchanges — MEXC and Gate.io — on the day of its official Token Generation Event (TGE), July 22, 2025, in addition to MultiBank.io and Uniswap. The $MBG Token will go live on: MultiBank.ioGate.ioMEXCUniswap This new dual listing will allow millions of users across both exchanges to seamlessly access and trade $MBG using their existing accounts, ensuring immediate market participation at launch. The Token Generation Event (TGE) is now approaching following the successful completion of two pre-sale rounds, where MultiBank Group issued 7 million tokens in Round 1 and 3 million tokens in Round 2 — both of which sold out within minutes. Naser Taher, Chairman and Founder of MultiBank Group said “With $MBG, we’re introducing a utility token built to deliver real-world value, transparency, and
SLB Announces Second-Quarter 2025 Results18.7.2025 12:50:00 CEST | Press release
Revenue of $8.55 billion increased 1% sequentially and decreased 6% year on year GAAP EPS of $0.74 increased 28% sequentially and decreased 4% year on year EPS, excluding charges and credits, of $0.74 increased 3% sequentially and decreased 13% year on year Net income attributable to SLB of $1.01 billion increased 27% sequentially and decreased 9% year on year Adjusted EBITDA of $2.05 billion increased 2% sequentially and decreased 10% year on year Cash flow from operations was $1.14 billion and free cash flow was $622 million Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the second-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716727689/en/ The exterior of the SLB headquarters in Houston, Texas. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2025Mar. 31, 2025Jun. 30, 2024SequentialYear-on-yearReve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom